Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

JW Therapeutics is a leading China-based cell therapy company with the most advanced progress for the CAR-T commercialization. The company aims to raise up to USD 300m.Backed by a strong shareholder Juno, the company has a strong foundation in the technology underlying the CAR-T therapy, which is demonstrated by its superior safety data for its Relma-cel. In addition to the CD19 target, the company has also obtained the technology for BCMA target. In addition, the company has T-cell receptor-based pipeline products for solid tumor (liver cancer) with anti-T cell exhaustion enhancement based on the technologies from Eureka and Lyell. We think both the management team and investor backing is strong.

JW Therapeutics is a leading China-based cell therapy company with the most advanced progress for the CAR-T commercialization. The company aims to raise up to USD 300m.Backed by a strong shareholder Juno, the company has a strong foundation in the technology underlying the CAR-T therapy, which is demonstrated by its superior safety data for its Relma-cel. In addition to the CD19 target, the company has also obtained the technology for BCMA target. In addition, the company has T-cell receptor-based pipeline products for solid tumor (liver cancer) with anti-T cell exhaustion enhancement based on the technologies from Eureka and Lyell. We think both the management team and investor backing is strong.

JW Therapeutics (药明巨诺) Pre-IPO: CAR-T Leader in China

China

JW (Cayman) Therapeutics Co. Ltd operates as a clinical stage therapy platform company. The Company offers developing, manufacturing and commercializing breakthrough cell-based immunotherapies forhematological cancers and solid tumors. JW (Cayman) Therapeutics provides services in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JW Therapeutics (2126 HK)

JW Therapeutics (药明巨诺) Pre-IPO: CAR-T Leader in China

JW Therapeutics is a leading China-based cell therapy company with the most advanced progress for the CAR-T commercialization. The company aims to...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)